LIXTE’s New Patent Enhances Cancer Treatment Innovations
Overview of the Patent
LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT and LIXTW) has recently garnered attention after receiving a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its U.S. Patent application numbered 16/467,721. This patent, titled "Oxabicycloheptanes for Modulation of Immune Response," specifically addresses the combination of its innovative LB-100 compound with a range of advanced cancer immunotherapies.
Insights from the CEO on the Patent Award
Bas van der Baan, the Chief Executive Officer of LIXTE, shared that this new patent significantly bolsters the company’s intellectual property portfolio. He highlighted that this accomplishment reflects LIXTE’s steadfast dedication to pioneering research aimed at delivering effective solutions for patients battling cancer.
Development of LB-100
LIXTE is actively developing LB-100, a first-in-class lead clinical PP2A inhibitor that aims to improve the effectiveness of cancer immunotherapy. Currently, the company is conducting clinical trials at prestigious institutions, including the Netherlands Cancer Institute (NKI) and The University of Texas MD Anderson Cancer Center in Houston.
Collaboration with Top Institutions
At NKI, LIXTE provides LB-100, while F. Hoffmann-La Roche Ltd. supplies atezolizumab (Tecentriq), a PD-L1 inhibitor, as part of a collaborative initiative known as the imCORE Network. This project aims to accelerate research in cancer immunotherapy through partnerships between academia and industry, specifically targeting patients with unresponsive metastatic colon cancer.
Additional Clinical Studies at MD Anderson
Moreover, another clinical trial at MD Anderson is exploring the effects of combining LB-100 with GSK’s dostarlimab-gxly, focusing on treatment options for ovarian clear cell carcinoma (OCCC).
Exclusive Licensing Agreement and Future Opportunities
The recent patent approval comes on the heels of LIXTE’s exclusive patent licensing agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) that was established earlier this year. This agreement provides LIXTE with the opportunity to further investigate innovative combination therapies that could potentially transform cancer treatment approaches.
About LIXTE Biotechnology Holdings, Inc.
LIXTE is a clinical-stage pharmaceutical company focused on discovering new pathways in cancer drug development. The company is dedicated to creating and commercializing effective cancer therapies. Their lead clinical candidate, LB-100, has demonstrated promising tolerance and anti-cancer activity in patients, paving the way for enhancing conventional chemotherapies and immunotherapies.
LIXTE is at the forefront of a new area of cancer biology called activation lethality. The company’s extensive patent portfolio supports their innovative strategies, with ongoing clinical trials currently targeting colon, ovarian, and sarcoma cancers.
Contact Information
For more information, LIXTE welcomes inquiries through the following contacts:
Email: info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Alternatively, you can reach out to Investor Relations at PondelWilkinson Inc.:
Email: pwinvestor@pondel.com
Roger Pondel: (310) 279-5965
Laurie Berman: (310) 279-5962
Frequently Asked Questions
What is the significance of LIXTE's recent patent?
This patent enables LIXTE to safeguard its innovative method of combining LB-100 with new cancer immunotherapies, thereby enhancing their research initiatives.
What is LB-100?
LB-100 is LIXTE’s leading clinical compound designed to inhibit PP2A, serving as a potentiator in cancer immunotherapy.
How does LIXTE collaborate with research institutions?
LIXTE partners with top institutions like NKI and MD Anderson to conduct clinical trials that utilize their compounds in conjunction with existing therapies.
What areas do LIXTE's clinical trials focus on?
LIXTE's trials concentrate on various cancers, including colon cancer and ovarian clear cell carcinoma, evaluating the effects of LB-100 in combination with other immunotherapies.
Where can I find more information about LIXTE?
For additional details about LIXTE and their ongoing projects, you can visit their official website directly.
